Drug Safety Information for RYBELSUS ()

FDA Safety-related Labeling Changes for RYBELSUS (SEMAGLUTIDE) Rx Drug: Safety Information Link

Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with RYBELSUS; Risk of serious gallbladder problems; Risk of hypoglycemia... Safety Label Update

FDA Adverse Event Summary for RYBELSUS (not avail) Unavailable